Media stories about VIVUS (NASDAQ:VVUS) have been trending somewhat positive on Tuesday, Accern reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. VIVUS earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.7115426583264 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Zacks: Brokerages Expect VIVUS, Inc. (NASDAQ:VVUS) to Post -$0.13 Earnings Per Share (americanbankingnews.com)
- The Magellan Midstream Partners LP (MMP) Shares Sold by Cabot Wellington LLC (currenthollywood.com)
- Vivus Pipeline Review, Analysis and Potential Catalysts (finance.yahoo.com)
- Technical Indicators Turn Indifferent For VIVUS (VVUS) - StockNewsGazette (stocknewsgazette.com)
- Watching the Indicators for VIVUS, Inc. (NASDAQ:VVUS) - Sparta Review (spartareview.com)
Separately, Zacks Investment Research upgraded VIVUS from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research report on Thursday, July 27th.
VIVUS (NASDAQ:VVUS) opened at 1.02 on Tuesday. The company’s 50-day moving average price is $1.17 and its 200 day moving average price is $1.12. VIVUS has a 52-week low of $0.99 and a 52-week high of $1.47. The company has a market capitalization of $107.93 million, a price-to-earnings ratio of 3.29 and a beta of 0.86.
ILLEGAL ACTIVITY NOTICE: “VIVUS (NASDAQ:VVUS) Getting Somewhat Favorable Media Coverage, Report Shows” was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://stocknewstimes.com/2017/08/15/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-vivus-nasdaqvvus-stock-price-updated-updated-updated.html.
About VIVUS
VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).
Receive News & Ratings for VIVUS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
